Open Access
Tableau II.
Essais cliniques actifs ou clôturés testant des inhibiteurs d’IDH1 et/ou d’IDH2 dans les hémopathies malignes myéloïdes avec mutation IDH1 et/ou IDH2, (à l’exclusion de l’ivosidenib et de l’énasidenib). NCT : numéro d’identification national.
| Cible | Composé | NCT | Phase | Titre |
|---|---|---|---|---|
| IDH1 | IDH305 | 02381886 | 1 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations |
| 06543381 | 1 | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | ||
| 02719574 | 1/2 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | ||
| 06445959 | 1b/2 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | ||
| Olutasidenib - |
06782542 | 2 | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy (OLUVENAZA) | |
| FT-2102 | ||||
| 06597734 | 2 | A Phase 2 Study Evaluating Olutasidenib in Combination with Hypomethylating Agents in Patients with IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | ||
| 06566742 | 2 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | ||
| 06668584 | 2 | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies | ||
| BAY1436032 | 03127735 | 1 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | |
| TQB3454 | 06218771 | 1/2 | A Study of TQB3454 Tablets in Patients With Blood Tumors | |
| IDH2 | TQB3455 | 06550713 | 1 | A Clinical Trial ofTQB3455 Tablets in Patients With Hematological Malignancies |
| HMPL-306 | 04764474 | 1 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | |
| 06387069 | 3 | A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia | ||
| IDH1 & IDH2 | Vorasidenib - |
02492737 | 1 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation |
| AG-881 | ||||
| LY3410738 | 04603001 | 1 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.